SUBSCRIBE
SUBSCRIBE

Remix Therapeutics

NEWS
Illustration of hand holding trophy with people coming out of trophy and celebrating
Job Trends
BioSpace Announces 2025 Best Places to Work in Biopharma
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
November 12, 2024
 · 
6 min read
 · 
Angela Gabriel
Pictured: A corporate building overlooking a freew
Money on the Move: SwanBio, Remix, Locus, Mirvie and More
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
May 18, 2022
 · 
8 min read
 · 
Hannah Chudleigh
Pete Smith, Ph.D., co-founder, president and CSO/C
Business
Startup Remix Inks RNA Collab with Janssen Valued at $1B
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
February 17, 2022
 · 
4 min read
 · 
Alex Keown
Pete Smith, Ph.D., co-founder, president and CSO/C
Business
Putting a New Spin on RNA, Remix Launches with $81 Million
The funds will be used to support the development of the company’s REMaster technology platform. In addition, Remix will now be able to advance its pipeline of RNA processing targeted therapeutics as well.
December 8, 2020
 · 
3 min read
 · 
Krystle Vermes
  • 2025 BPTW Badge - RBG.png
JOBS
IN THE PRESS
Press Releases
Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)
November 20, 2024
 · 
4 min read
Press Releases
Remix Therapeutics™ Announces Publication in Science that Reveals Unprecedented Insights into Spliceosome Regulation and Alternative Splicing
November 1, 2024
 · 
3 min read
Press Releases
Remix Therapeutics Announces Participation in Jefferies London Healthcare Conference
October 29, 2024
 · 
1 min read
Press Releases
Remix Therapeutics™ to Present Preclinical Data Demonstrating Tumor Regressions Induced by REM-422 in Adenoid Cystic Carcinoma Patient-Derived Xenograft Models at the 2024 EORTC-NCI-AACR Symposium
October 16, 2024
 · 
4 min read
Press Releases
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration
July 11, 2024
 · 
2 min read
Business
Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
June 18, 2024
 · 
2 min read
Drug Development
Remix Therapeutics™ to Present Preclinical Data Demonstrating Anti-Tumor Activity of REM-422 in AML at the European Hematology Association (EHA) 2024 Congress
June 13, 2024
 · 
4 min read
Genetown
Remix Therapeutics Announces Participation in Jefferies 2024 Healthcare Conference
May 28, 2024
 · 
1 min read
Drug Development
Remix Therapeutics Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS)
May 2, 2024
 · 
4 min read
Genetown
Remix Therapeutics to Participate in Upcoming Investor Conferences
February 7, 2024
 · 
1 min read
Load More